Drugs / IDX-1197
Trials 3 · a red edge is where a trial was stopped
| Phase | Registry id | Dates | Indication | Sponsor | Status | Outcome |
|---|---|---|---|---|---|---|
| Phase 11 trial | ||||||
| Phase 1 | NCT05202912 | Jan → Jul 2022 | — | Idience Co., Ltd. | Completed | No outcome recorded |
| Phase 1/22 trials | ||||||
| Phase 1/2 | NCT04725994 | Jun 2021 → Jul 2026 overdue | gastric cancer | Idience Co., Ltd. | Active not recruiting | No outcome recorded |
| Phase 1/2 | NCT04174716 | Nov 2019 → Mar 2023 | cancer | Idience Co., Ltd. | Completed | No outcome recorded |
Evidence & citations 3 cited values
Every value below carries the sentence it was read from. 3 sources stand behind the page.
| Field | Value | Cited text |
|---|---|---|
| Known as | IDX-1197 | ClinicalTrials.gov intervention name — accepted as the source's own label NCT04174716 ↗ |
| Action | Inhibit | “a PARP Inhibitor” NCT04174716 ↗ |
| Route | Oral | “After Single Oral Administration” NCT05202912 ↗ |